BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37969054)

  • 1. BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype.
    Zhang X; Guo X
    Cytometry B Clin Cytom; 2024 Mar; 106(2):146-148. PubMed ID: 37969054
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of donor cell leukemia driven by a de novo NRAS mutation with complex karyotype.
    Jeong D; Gu JY; Seo MS; Lee JS; Chang YH; Seong MW; Yoon SS; Kim HK
    Ann Hematol; 2023 Jul; 102(7):1951-1952. PubMed ID: 37256306
    [No Abstract]   [Full Text] [Related]  

  • 3. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
    Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
    Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple point
    Durinikova A; Folta A; Pardy F; Svaton J; Drncova M; Weinbergerova B; Cetkovsky P; Racil Z; Jindra P; Szotkowski T; Zak P; Mayer J; Jeziskova I
    Leuk Lymphoma; 2022 Dec; 63(13):3237-3240. PubMed ID: 36047997
    [No Abstract]   [Full Text] [Related]  

  • 5. NRAS
    Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
    Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].
    Li TT; Li J; Geng YH; Zhang F; Liu L; Yang YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):76-81. PubMed ID: 32027256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and NRAS p.Gly61Arg mutation.
    Ganapathi SS; Raikar SS; Yatsenko SA; Djokic M; Bukowinski A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1372. PubMed ID: 33784031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.
    Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Ghali HH; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Sughayer MA; Rihani R; Madanat FF; Inoshita T; Kamata M; Koike K
    Pediatr Blood Cancer; 2015 Dec; 62(12):2157-61. PubMed ID: 26222068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.
    Wang S; Wu Z; Li T; Li Y; Wang W; Hao Q; Xie X; Wan D; Jiang Z; Wang C; Liu Y
    Sci Rep; 2020 Jul; 10(1):12152. PubMed ID: 32699322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients.
    Zhang Y; Wang F; Chen X; Liu W; Fang J; Wang M; Teng W; Cao P; Liu H
    Front Med; 2019 Apr; 13(2):229-237. PubMed ID: 29806051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.
    Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
    Genes Chromosomes Cancer; 2021 Jun; 60(6):426-433. PubMed ID: 33433047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
    Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
    Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
    PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-leukemic effects of simvastatin on NRAS
    Jang J; Lee J; Jang JH; Jung CW; Park S
    Mol Biol Rep; 2019 Dec; 46(6):5859-5866. PubMed ID: 31452046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
    Zhang X; Guo X
    Leuk Lymphoma; 2019 Nov; 60(11):2844-2846. PubMed ID: 31050567
    [No Abstract]   [Full Text] [Related]  

  • 17. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of
    Jin H; Zhu Y; Hong M; Wu Y; Qiu H; Wang R; Jin H; Sun Q; Fu J; Li J; Qian S; Qiao C
    Leuk Lymphoma; 2021 Oct; 62(10):2428-2437. PubMed ID: 34024223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
    Thomay K; Behrens YL; Lentes J; Wittner N; Wittig V; Rothe D; Steinemann D; Schlegelberger B; Göhring G
    Leuk Lymphoma; 2018 Oct; 59(10):2478-2481. PubMed ID: 29384408
    [No Abstract]   [Full Text] [Related]  

  • 20. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.